Area of research
Public Health, Environmental and Occupational Health · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Medicine, Internal medicine, Oncology, Lymphoblastic Leukemia, Pediatrics, and Cumulative incidence.
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/<i>KMT2A</i>Rearrangements in a Modern Therapy Era: A Retrospective International Study
Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120
PAX5 Fusion Genes are Frequent in Poor Risk Childhood Acute Lymphoblastic Leukaemia and Can Be Targeted with BIBF1120
An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia
Setting up and sustaining blood and marrow transplant services for children in middle-income economies: an experience-driven position paper on behalf of the EBMT PDWP
Recurrent genetic fusions redefine <i>MLL </i>germ line acute lymphoblastic leukemia in infants
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp>‐<scp>BFM ALL</scp> protocols
Genetic Risk Factors for VIPN in Childhood Acute Lymphoblastic Leukemia Patients Identified Using Whole-Exome Sequencing
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B‐Cell Lymphoma treated with the<scp>AIEOP LNH</scp>‐97 protocol
<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study
Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol
Long‐term results of the AIEOP LNH‐97 protocol for childhood lymphoblastic lymphoma
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): A model for sustainable development in pediatric oncology
What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?
Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia"
Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia